Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Open-Label, Single-Dose, Three-Way Crossover Study Assessing the Drug-Drug Interaction Between ZX008 (Fenfluramine Oral Solution) and Stiripentol/Clobazam/Valproate in Healthy Subjects

Trial Profile

A Phase I, Randomized, Open-Label, Single-Dose, Three-Way Crossover Study Assessing the Drug-Drug Interaction Between ZX008 (Fenfluramine Oral Solution) and Stiripentol/Clobazam/Valproate in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fenfluramine (Primary) ; Clobazam; Stiripentol; Valproate
  • Indications Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Seizures
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 19 Oct 2018 Results published in the International Journal of Clinical Pharmacology and Therapeutics
    • 03 Jan 2018 New trial record
    • 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top